Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation

Osimertinib was approved by the Food and Drug Administration in 2018 for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients. At first, osimertinib was used only for patients with acquired T790  M mutations after 1st and/or 2nd generation EGFR tyrosine kinase inhibitor (TKI) treatment, but it more recently began to be used in first line treatment of EGFR-mutant patients.[1] Despite good initial responses, patients developed resistance to second-line osimertinib treatment, with a median t ime to progression of 10.1 months.[2] Several mechanisms to explain this resistance have been identified, including an acquired v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutation.[2] Treatment options for patients with acquired BRAF V600E have not been established and are still in an early phase of development.

Source: Lung Cancer - June 3, 2020 Category: Cancer & Oncology Authors: Pei Meng, Bart Koopman, Klaas Kok, Arja ter Elst, Ed Schuuring, L éon C. van Kempen, Wim Timens, T. Jeroen N. Hiltermann, Harry J.M. Groen, Anke van den Berg, Anthonie J. van der Wekken Source Type: research